Navigation Links
Cellular Biomedicine Group Announces Completion of Patient Enrollment for Phase I Clinical Trial for Liver Cancer
Date:8/22/2013

PALO ALTO, Calif., Aug. 22, 2013 /PRNewswire/ -- Cellular Biomedicine Group (OTCQB: CBMG) today announced that it has completed patient enrollment for its Phase I trial to evaluate the safety and preliminary efficacy of TC-DC (Tumor Stem Cell Specific Dendritic Cell) therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer.

The Phase I clinical trial for TC-DC therapy for HCC is an open label clinical trial conducted with Shanghai's PLA 85 Hospital, which is a Liver Disease Center. The trial will evaluate the safety and efficacy in lowering the incidence of tumor recurrence and metastasis by means of autologous immune cell therapy in primary HCC patients following standard tumor resection and TACE chemotherapy.

Dr. Cheng Xiang (Chase) Dai, Cellular Biomedicine Group's VP and GM of the Autologous Products Business Unit, said, "We are pleased with this important achievement in the advancement of our therapy for liver cancer, and are on schedule to complete the Phase I trial in Q4 of this year."

About Hepatocellular Carcinoma
Forty-five percent of the world's HCC patients are in China, with over 300,000 new patients diagnosed every year. The therapies commonly offered to most patients are surgery and local chemotherapy, with a 2-year recurrence rate of 51% and median survival time of 13 months.

About TC-DC Therapy for Hepatocellular Carcinoma
TC-DC therapy takes a sample of the patient's own dendritic cells, which are the 'trainer' cells of effecter immune cells, and a sample of the patient's tumor stem cells, and co-cultures them together in the lab. The dendritic cells will learn the characteristics of the patient's own tumor stem cells, and are reintroduced to the patient's body as a vaccine, where they can 'train' the immune system to fight and destroy the tumor stem cells, which are the root cause of tumor recurrence and metastasis.

"One of the primary difficulties in administering effective cancer therapy is in the uniqueness of the disease; no two cancers are the same," explained Dr. William Cao, President of CBMG, "Therefore, we source both immune and cancer stem cells directly from the patient so that each treatment is specific to each individual. In addition, rather than break down the cancer stem cell and use a portion of it, we use the whole cancer stem cell as the antigen source to stimulate the patient's own dendritic cells."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@CellBioMedGroup.com


'/>"/>
SOURCE Cellular Biomedicine Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellular Biomedicine Group Appoints Director of Medical Research
2. Cellular Biomedicine Group Announces Enrollment Milestone for Phase I Clinical Trial for Liver Cancer
3. Study Shows Whole-Cell Vaccine was More Effective than Acellular Vaccine During California Pertussis Outbreak
4. Exosome Diagnostics Presents Data Demonstrating Clinical Applications of Exosome Technology in Brain Cancer, Prostate Cancer, and Alzheimers Disease at the International Society for Extracellular Vesicles 2013 Annual Meeting
5. Cellular Dynamics International Opens Facility in California, Leasing Space from the Buck Institute to Derive and Bank Human Induced Pluripotent Stem Cells
6. Cellular Biomedicine Group Marks the Launch of China Clinical Trial for TC-DC Therapy for Hepatocellular Carcinoma
7. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
8. Intra-Cellular Therapies Announces Completion of Phase I Single Rising Dose Trial of First-in-Class Selective Phosphodiesterase 1 (PDE1) Inhibitor and Reports Top-line Safety and Pharmacokinetic Findings
9. Arteriocyte Receives FDA Approval to Initiate Cellular Therapy Trial for Treatment of Thermal Burn Wounds in Wounded Warriors
10. The Treatment Landscape for Hepatocellular Carcinoma Will Change Dramatically Over the Next Ten Years Due to the Launch of New Therapies in the United States and EU5
11. EastBridge Investment Group Announces Merger with Cellular Biomedicine Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... instruments commonly used in laboratories. These may range from ... condensers. Laboratory glassware is made from borosilicate glass because ... Laboratory plasticware, on the other hand, started gaining popularity ... it was easier to replace glass with plastic in ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 ... of new health technologies, announced today " 10 Year ... in health tech over the past ten years.   ... nearly a decade, Health 2.0 has served as the ... and connected with thousands of technologies, companies, innovators, and ...
(Date:2/11/2016)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... development services for the pharmaceutical and biotechnology industries, ... in its Charleston, SC ... recent investments. Charleston ... with small-scale lyophilization. The site has invested in ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... According to an article published February 4th on ... portion of hernia repairs throughout the United States. Commenting on this article, Beverly Hills ... this trend has not only been expected, but it seems to be a natural ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the advanced skills ... recruit top students from U.S. universities who will draw from Siemens’ deep ...
(Date:2/12/2016)... Church, VA (PRWEB) , ... February 12, 2016 ... ... Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... issue in the life cycle of pharmaceutical products, garnering increased attention from all ...
(Date:2/12/2016)... ... ... Coco Libre, the maker of coconut water beverages with a purpose, is ... Coco Libre will offer musicians and celebrities the company’s signature Organic Coconut Water, a ... suite, held this year at the W Hollywood Hotel, has become a pre-show “must” ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a ... the integration of Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and ... intelligence (BI) to their small and medium business (SMB) clients. , ...
Breaking Medicine News(10 mins):